Top-News
Werbung
Attraktive Knock-Outs auf AbbVie Inc
Typ Hebel Bid / Ask WKN
Call
2,1 9,64 € / 9,67 €
SB78GS
Typ Hebel Bid / Ask WKN
Den Basisprospekt sowie endgültige Bedingungen und Basisinformationsblätter erhalten Sie bei Klick auf das Dokument-Icon. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Alle Knock-Outs auf AbbVie Inc

AbbVie Aktie News

Aktie
WKN:  A1J84E ISIN:  US00287Y1091 US-Symbol:  ABBV Branche:  Pharmazeutika Land:  USA
234,00 $
+0,00 $
0,00%
201,86 € 01:00:00 Uhr
Depot/Watchlist
Marktkapitalisierung *
353,90 Mrd. €
Streubesitz
25,26%
KGV
73,73
Dividende
1,64 $
Dividendenrendite
0,71%
neu: Nachhaltigkeits-Score
46 %
Index-Zuordnung
S&P 500
Weiter aufwärts? Long handeln - Jetzt mit Hebel 16,63: GU6TF1
Werbung

AbbVie News

14.11.25 - PR Newswire
AbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer
AbbVie Partners with Award-​Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer PR Newswire
13.11.25 - PR Newswire
AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™
AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™ PR Newswire
12.11.25 - PR Newswire
Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence
Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence PR Newswire
31.10.25 - PR Newswire
AbbVie Reports Third-Quarter 2025 Financial Results
AbbVie Reports Third-​Quarter 2025 Financial Results PR Newswire
29.10.25 - wallstreetONLINE Redaktion
Earnings Preview – Teil 2: Nach Fed-Enttäuschung: Am Donnerstag müssen Amazon, Apple und Co. liefern!
Diese in den kommenden Tagen (KW44) anstehenden US-​Quartals­zahlen müssen Anlegerinnen und Anleger kennen: Herausforderungen, Erwartungen und die aktuell ...
29.10.25 - PR Newswire
The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year
The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year PR Newswire
29.10.25 - PR Newswire
AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo
AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo PR Newswire
28.10.25 - PR Newswire
Allergan Aesthetics and Girls Inc., in Partnership with SkinSpirit, Inspire Future Women Leaders in STEM
Allergan Aesthetics and Girls Inc., in Partnership with SkinSpirit, Inspire Future Women Leaders in STEM PR Newswire
26.10.25 - wallstreetONLINE Redaktion
Earnings Preview – Teil 2: Hohe Bewertungen erlauben keine Fehler: Amazon, Apple und Co. müssen liefern!
Diese in den kommenden Tagen (KW44) anstehenden US-​Quartals­zahlen müssen Anlegerinnen und Anleger kennen: Herausforderungen, Erwartungen und die aktuell ...
21.10.25 - PR Newswire
The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients
The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients PR Newswire
20.10.25 - PR Newswire
RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor
RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-​to-Head Study in Rheumatoid Arthritis Patients Who Have Failed ...
17.10.25 - PR Newswire
AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin
AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin PR Newswire
13.10.25 - PR Newswire
U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease
U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease PR Newswire
13.10.25 - PR Newswire
AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors
AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors PR Newswire
09.10.25 - PR Newswire
SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer
SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer PR Newswire
06.10.25 - PR Newswire
AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor
AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor PR Newswire
02.10.25 - PR Newswire
AbbVie to Host Third-Quarter 2025 Earnings Conference Call
AbbVie to Host Third-​Quarter 2025 Earnings Conference Call PR Newswire
01.10.25 - wallstreetONLINE Redaktion
Aktien kräftig im Plus: Medikamenten-Deal entfesselt Pharma-Aktien
Die Aktienkurse großer US-​Pharmaunternehmen haben am Dienstag kräftig zugelegt, nachdem Präsident Donald Trump eine Vereinbarung mit Pfizer bekanntgab.Pfizer senkt ...
01.10.25 - PR Newswire
Natrelle® Awarded Supplier Agreement from Vizient
Natrelle® Awarded Supplier Agreement from Vizient PR Newswire
30.09.25 - PR Newswire
AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S.
AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S. PR Newswire

Newssuche

Videos

newspaper
17.11.25 -23,81%
Technical Trading: DAX Long, weil...
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »